Search results for "Antibodies."

showing 10 items of 1857 documents

Incidence of lineage promiscuity in acute myeloblastic leukemia: Diagnostic implications of immunoglobulin and T-cell receptor gene rearrangement ana…

1988

Abstract Sixty-nine blood or bone marrow samples from both children and adults with acute myeloblastic leukemia (AML) were investigated to elucidate the frequency of immunoglobulin (IG) and T-cell receptor (TCR)-gene rearrangements. Non-germline configuration for the IG heavy chain (h) gene was detected in the specimens of nine patients of various subtypes according to the French-American-British classification (FAB), including FAB M1, M2, M4 and M5. Rearrangement of the IG kappa chain (k) gene was present in one of these cases which simultaneously revealed a rearranged TCR-beta (b) chain gene. In another two AML samples we found TCR-b gene rearrangements, in one case in combination with an…

AdultImmunoglobulin geneCancer ResearchAcute myeloblastic leukemiaCD19medicineHumansGene Rearrangement beta-Chain T-Cell Antigen ReceptorChildGenes ImmunoglobulinbiologyAntibodies MonoclonalCell DifferentiationHematologyGene rearrangementmedicine.diseaseMolecular biologyLeukemia Myeloid AcuteLeukemiaPhenotypeOncologyTerminal deoxynucleotidyl transferaseT-Cell Receptor Genebiology.proteinAntibodyImmunoglobulin Heavy ChainsLeukemia Research
researchProduct

Elevated levels of anti-endotoxin antibodies in patients with bilateral idiopathic acute anterior uveitis

2010

. Purpose:  Endotoxins have been proved to be responsible for acute anterior uveitis (AAU) in animals in a well-established experimental model of endotoxin-induced uveitis (EIU). The purpose of our study was the detection of antibodies against endotoxins of selected enterobacteria in the serum of patients with idiopathic AAU and searching for correlations between the levels of these antibodies and the presence of HLA-B27 antigen as well as characteristic signs of EIU such as bilaterality and the absence of spontaneous recurrences of the disease. Methods:  Reactions of serum IgG antibodies with lipopolysaccharides (LPSs) of Escherichia coli O1, E. coli O10, E. coli O111, E. coli J5, and Kleb…

AdultLipopolysaccharidesMaleKlebsiella pneumoniaeEnzyme-Linked Immunosorbent AssayInflammationDiseaseEye Infections BacterialAntigenGram-Negative BacteriaEscherichia coliHumansMedicineHLA-B27 Antigenbiologybusiness.industryIncidence (epidemiology)General MedicineMiddle Agedmedicine.diseasebiology.organism_classificationAntibodies BacterialUveitis AnteriorKlebsiella pneumoniaeOphthalmologyImmunoglobulin GAcute DiseaseImmunologybiology.proteinEtiologyFemaleAntibodymedicine.symptomGram-Negative Bacterial InfectionsbusinessUveitisActa Ophthalmologica
researchProduct

Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis.

2004

Objective— Functionally interactive proteases of the plasminogen/plasmin and the matrix metalloproteinase (MMP) system degrade and reorganize the extracellular matrix of the vessel wall in atherosclerosis. Here we investigated whether such proteases are able to confer atherogenic properties onto low density lipoprotein by nonoxidative modification. Methods and Results— Similar to the recently described enzymatically-modified low-density lipoprotein (E-LDL), native LDL exposed to plasmin or matrix MMP-2 or MMP-9 and cholesterylester-hydrolase (CEH) showed extensive deesterification, with ratios of free cholesterol to total cholesterol rising to 0.8 compared with 0.2 in native LDL. When the …

AdultLipoprotein modificationProteasesAdolescentPlasminArteriosclerosisBlotting WesternMatrix metalloproteinaseComplement Hemolytic Activity AssayMonocyteschemistry.chemical_compoundmedicineHumansTrypsinFibrinolysinComplement ActivationCells CulturedAgedbiologyMacrophagesAntibodies MonoclonalSodium Dodecyl SulfateLipoprotein(a)Middle AgedSterol EsteraseCell biologyLipoproteins LDLC-Reactive ProteinchemistryBiochemistryMatrix Metalloproteinase 9Low-density lipoproteinbiology.proteinMatrix Metalloproteinase 2lipids (amino acids peptides and proteins)Electrophoresis Polyacrylamide GelCardiology and Cardiovascular MedicinePlasminogen activatormedicine.drugLipoproteinArteriosclerosis, thrombosis, and vascular biology
researchProduct

Interaction of alcohol intake and cofactors on the risk of cirrhosis.

2010

OBJECTIVE: Evaluation of the interaction between alcohol intake and cofactors [hepatitis B virus (HBV), hepatitis C virus (HCV), body mass index] and coffee consumption on the risk of cirrhosis. DESIGN: Seven hundred and forty-nine consecutive patients with chronic liver disease referring to units for liver or alcohol diseases in Italy during a 6-months period. Teetotalers were excluded. The odds ratios (OR) for cirrhosis were evaluated using chronic hepatitis cases as the control group. RESULTS: An alcohol intake of more than 3 units/day resulted associated with the likelihood of cirrhosis both in males (OR 4.3; 95% CI=2.5-7.3) and in females (OR 5.7; 95% CI=2.3-14.5). A multiplicative int…

AdultLiver CirrhosisMaleHepatitis B virusAlcohol Drinkingalcohol cirrhosis coffeeHepacivirusCoffeeRisk Assessmentcirrhosis coffeeBody Mass IndexNORisk FactorsOdds RatioHumansCIRRHOSISAgedHepatitis B Surface AntigensalcoholHepatitis C AntibodiesMiddle AgedHepatitis BHepatitis CItalyCase-Control StudiesDisease ProgressionRNA ViralFemale
researchProduct

High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance

2004

The emergence of drug-resistant virus in hepatitis B virus patients treated with lamivudine is well documented. However. its clinical impact in the long-term treatment of anti-HBe positive compensated cirrhotic patients is not well known. In this study, we treated 22 consecutive patients with anti-HBe compensated cirrhosis with lamivudine for a median period of 42 months. All patients responded to lamivudine, but viral breakthrough occurred in 13 patients (59%) between 9 and 42 months of therapy due to the emergence of a mutant strain. During the follow-up, 11 developed hepatocellular carcinoma. Of these, 10 occurred soon after the emergence of viral resistance, generally showing aggressive…

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisLAMIVUDINEmedicine.disease_causeRisk AssessmentGastroenterologyVirusVirologyInternal medicineDrug Resistance ViralHumansMedicineHepatitis B e AntigensHEPATOCELLULAR CARCINOMAHepatitis B AntibodiesCIRRHOISIS; HEPATOCELLULAR CARCINOMA; LAMIVUDINE; HEPATITIS B; PRE-CORE MUTANTHepatitis B virusCirrhosiHepatologybusiness.industryCIRRHOISISLamivudineMiddle AgedHepatitis Bmedicine.diseaseHepatitis B Core AntigensViral BreakthroughPRE-CORE MUTANTInfectious DiseasesHepatocellular carcinomaRelative riskMutationHEPATITIS BReverse Transcriptase InhibitorsFemalePrecore mutantbusinessmedicine.drugJournal of Viral Hepatitis
researchProduct

The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

2019

Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHBV reactivationHbv markersHbv reactivationPrevalenceHbv vaccinationHepacivirusChronic liver diseaseAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinePrevalencemedicineHumansHepatitis B AntibodiesReimbursementAgedHepatitis B Surface AntigensHepatologyCoinfectionbusiness.industryGastroenterologyHCV therapyvirus diseasesHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseChronic HCV infection; HBV reactivation; HBV/HCV coinfection; HCV therapydigestive system diseasesHBV/HCV coinfectionItalyChronic HCV infection030220 oncology & carcinogenesisDNA ViralFemaleVirus Activation030211 gastroenterology & hepatologybusiness
researchProduct

Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?

2005

Coeliac disease (CD) is found in 5-10% of patients with chronically abnormal liver tests and no obvious cause of liver disease. In this population the efficacy of screening for CD by anti-tissue transglutaminase (anti-tTG) may be impaired by the high rate of positive anti-tTG found in chronic liver disease.To evaluate the prevalence of coeliac disease and the role of anti-tTG in patients with non-viral, non-autoimmune chronic and no obvious cause of liver damage.Out of 2,512 consecutive patients with abnormal liver tests, 168 (118 men, 50 women; mean age 40.7 +/- 12.6 years) were defined, on the basis of clinical data and liver biopsy, as NAFLD or cryptogenic chronic hepatitis. All were tes…

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyAdolescentTissue transglutaminaseDuodenumBiopsyGastroenterologyCoeliac diseaseGTP-Binding ProteinsInternal medicineBiopsymedicineHumansMass ScreeningIn patientProtein Glutamine gamma Glutamyltransferase 2Aspartate AminotransferasesDuodenoscopyMass screeningAgedAutoantibodiesHepatitis ChronicHepatitisTransglutaminasesHepatologybiologymedicine.diagnostic_testbusiness.industryLiver DiseasesGastroenterologynutritional and metabolic diseasesAlanine TransaminaseMiddle Agedmedicine.diseasedigestive system diseasesImmunoglobulin AFatty LiverCeliac DiseaseLiverImmunoglobulin Gbiology.proteinFemaleAbnormal liverAntibodybusinessThe American journal of gastroenterology
researchProduct

Long-term follow-up of hepatitis C virus-positive patients with persistently normal serum transaminases

2013

Material and methods. This study prospectively evaluated the progression of liver disease in a group of anti-HCV-positive patients with persistently normal ALT levels (PNALT) who were HCV-RNA positive. Patients selected for this study were those who presented with PNALT according to the Italian Association for the Study of the Liver (AISF) criteria in the year 1995/96 and underwent liver biopsy. They were divided into two groups according to their ALT evolution. Forty-five patients were included in this study. Results. After a median follow-up time of 180 months twenty-five of them maintained PNALT, but two of these developed liver cirrhosis (LC) in a mean time of 174 and 202 months, respec…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisLong term follow upSpecialties of internal medicineNormal serumChronic hepatitis CGastroenterologyAntiviral AgentsBody Mass IndexLiver diseaseInterferon treatmentInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesUltrasonography Doppler ColorChronic hepatitis C. Persistently normal transaminases. Liver histology. Progression of disease. Interferon treatment.Proportional Hazards ModelsHepatologymedicine.diagnostic_testbusiness.industrySignificant differenceHistologyAlanine TransaminaseGeneral MedicineHepatitis C AntibodiesHepatitis C ChronicMiddle Agedmedicine.diseaseSurgeryHepatitis C Virus PositiveLiverRC581-951Liver biopsyDisease ProgressionElasticity Imaging TechniquesRNA ViralFemaleBiopsy Large-Core NeedlePersistently normal transaminasesbusinessLiver histologyProgression of disease
researchProduct

Characteristics of hepatocellular carcinoma in Italy.

1998

This study aimed to assess the main features of hepatocellular carcinoma at the time of diagnosis in Italy, particularly in relation to the presence or absence of underlying cirrhosis, hepatitis virus marker patterns, age of the subjects and alpha-foetoprotein values.A total of 1148 patients with hepatocellular carcinoma seen at 14 Italian hospitals in the 1-year period from May 1996 to May 1997 were the subjects of this prevalence study. Both newly diagnosed cases (incident cases) and cases diagnosed before May 1996 but still attending the hospitals during the study period (prevalent cases) were included.We found that 71.1% of cases were positive for hepatitis C virus antibodies but negati…

AdultLiver CirrhosisMalemedicine.medical_specialtyHBsAgCarcinoma HepatocellularHepatitis C virusmedicine.disease_causeGastroenterologyAge DistributionInternal medicineHepatitis VirusesmedicinePrevalenceHumansSex DistributionAgedHepatitisAged 80 and overHepatitis B Surface AntigensHepatologybusiness.industryIncidence (epidemiology)Liver NeoplasmsLiver cancer; risk factors; ItalyHepatitis BHepatitis C AntibodiesMiddle Agedmedicine.diseaseLogistic ModelsItalyHepatocellular carcinomaImmunologyRegression AnalysisFemalealpha-FetoproteinsLiver cancerbusinessViral hepatitisJournal of hepatology
researchProduct

Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe

2001

The aim of this study was to evaluate the distribution and clinical significance of hepatitis C virus (HCV) genotypes in European patients with compensated cirrhosis due to hepatitis C (Child class A) seen at tertiary referral centres. HCV genotypes were determined by genotype-specific primer PCR in 255 stored serum samples obtained from cirrhotics followed for a median period of 7 years. Inclusion criteria were biopsy-proven cirrhosis, absence of complications of cirrhosis and exclusion of all other potential causes of chronic liver disease. The proportion of patients with types 1b, 2, 3a, 1a, 4 and 5 were 69%, 19%, 6%, 5%, 0.5% and 0.5%, respectively. Kaplan-Meier 5-year risk of hepatocel…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisHepacivirusHepatitis C virusHepacivirusAntibodies ViralChronic liver diseasemedicine.disease_causeAntiviral AgentsGastroenterologyDisease-Free SurvivalStatistics NonparametricSex FactorsSDG 3 - Good Health and Well-beingVirologyInternal medicineHumansMedicineDecompensationLongitudinal StudiesAgedProportional Hazards ModelsHepatologybiologybusiness.industryAge FactorsInterferon-alphaTransfusion ReactionHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CEuropeTreatment OutcomeInfectious DiseasesRelative riskHepatocellular carcinomaRNA ViralFemalebusiness
researchProduct